A股異動 | 健友股份漲逾4% 子公司獲美國FDA暫時批准文號
格隆匯4月22日丨健友股份(603707.SH)現報57.07元,漲4.33%,暫成交1.7億元,最新總市值410億元。健友股份昨日盤後公佈,公司子公司健進製藥近日收到美國食品藥品監督管理局(“FDA”)通知,健進製藥向美國FDA申報的注射用鹽酸苯達莫司汀ANDA申請已獲得暫時批准。此次獲得美國FDA的暫時批准文號,標誌着該產品滿足仿製藥的所有審評要求,但需在相關專利到期並得到美國FDA最終批准後才可獲得在美國市場銷售該產品的資格。公司將積極推動該產品在美國市場的上市準備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.